1. Introduction {#sec1}
===============

Renal cell carcinoma represents a rare site for intraocular metastasis. Given the severity of systemic disease in many of these cases, intraocular treatment options remain limited and can be associated with significant ocular morbidity with limited benefit for vision restoration. The authors describe a novel treatment for renal cell carcinoma metastasis to the ciliary body. The ciliary body tumor was treated successfully with intravitreal bevacizumab, which provided complete tumor regression following three intravitreal injections, offering a relatively non-invasive method of treatment and significant vision improvement.

2. Case report {#sec2}
==============

A 70-year-old Caucasian man presented for decreased vision in the left eye. Past medical history was significant for stage IV renal cell carcinoma (RCC), clear cell type, that was diagnosed two years previously. The RCC had metastasized to lung, bone, mediastinum, adrenal glands, and lymph nodes. There has been progression of the RCC despite treatment with Pazopanib, Axitinib, and Afinitor. On presentation, best-corrected visual acuity was 20/20 and 20/80, respectively. Intraocular pressures were 8 mmHg in the right eye and 10 mmHg in the affected left eye. Slit-lamp exam of the right eye was normal. Exam of the left eye showed a flesh-like, pink, vascular mass in the angle between 4 and 6 o\'clock that measured 2.5mm in length and 1.5mm in height. The lesion was associated with a 2mm layered hyphema adjacent to the mass ([Fig. 1](#fig1){ref-type="fig"}). Given the history of systemic metastasis and the location of the tumor, the tumor was most likely a ciliary body mass secondary to metastatic RCC. Fundus examination was normal in both eyes. Intravitreal bevacizumab (1.25mg/0.05 cc) was injected into the left eye. Eleven days later, vision improved to 20/30, and the size of the mass decreased to 1.5mm in length and 0.75mm in height with resolution of the hyphema ([Fig. 2](#fig2){ref-type="fig"}). Four weeks later, the patient received a second intravitreal bevacizumab injection and then a third injection six weeks later. The subsequent visit showed complete regression of the mass on exam ([Fig. 3](#fig3){ref-type="fig"}). The patient continues to receive intravitreal bevacizumab injections every 8 weeks to maintain resolution of the metastatic tumor.Fig. 1Ciliary body tumor on presentation. The tumor measures 2.5mm in horizontal length and 1.5 mm in vertical height. There is an adjacent layered hyphema.Fig. 1Fig. 2Ciliary body tumor following first bevacizumab injection. The tumor is regressing and measures 1.5mm in horizontal length and 0.7mm in vertical height. The hyphema has resolved.Fig. 2Fig. 3Complete regression of ciliary body tumor following three bevacizumab injections. There is no tumor seen on examination.Fig. 3

3. Discussion {#sec3}
=============

Renal cell carcinoma accounts for 3% of all adult malignancies.[@bib1] The majority of metastases occur in lung and bone, but can spread to any organ in the body.[@bib2] Intraocular metastases from RCC have been infrequently reported in the literature. Even fewer are metastatic disease to the ciliary body and iris. Ferry and Font studied 227 patients with ocular metastatic disease; there were 196 intraocular metastases and 7 of these were from the kidney.[@bib3] Shields et al. performed a survey of 520 eyes with uveal metastases and found 2% of eyes with ciliary body metastases and 9% with iris metastases; only one case from the ciliary body and one from the iris were from the kidney.[@bib4] Boniuk and et performed a review of the literature and found only 4 cases of ciliary body metastases from RCC.[@bib5] Due to the lack of RCC metastases to the ciliary body or iris reported in the literature, there have been no consensus on the treatment of these metastatic tumors. Shields et al. reported external beam radiation, plaque radiation, resection, and a combination of these methods for possible treatment options.[@bib4] Haimovici et al. made the observation that the metastases from RCC generally respond well to local irradiation.[@bib6] Another patient was treated with radiotherapy, plaque radiation, and finally enucleation.[@bib7]

However, it is well-known in the oncology literature that intravenous bevacizumab used either as monotherapy or in combination with other chemotherapy agents are effective treatment options for RCC.[@bib8], [@bib9] This is supported by the fact that RCC patients have elevated vascular endothelial growth factor (VEGF) levels.[@bib10] Therefore, it would make sense that an anti-VEGF agent, such as bevacizumab, would be a good treatment for RCC. There have been no cases, to our knowledge, of successful treatment of ciliary body metastases from RCC with intravitreal bevacizumab. There is one case of a ciliary body RCC metastasis that failed two intravitreal Avastin injections, but did respond to proton beam radiotherapy.[@bib11] In the past, uveal tumors in the literature have been treated with external beam radiation, plaque radiation, and tumor resection. However, intravitreal bevacizumab is much less invasive and vision-preserving and can possibly be considered as an effective treatment option for patients who are too ill to undergo surgery or have failed radiation. We report a case of ciliary body metastasis from RCC, which showed complete resolution of the tumor following intravitreal bevacizumab injections. The success of the treatment and the rarity of the presentation make this a unique case.

4. Conclusions {#sec4}
==============

We propose that intravitreal bevacizumab can be an effective and minimally invasive treatment for patients with ciliary body tumors from RCC. Our patient had complete regression of the tumor on examination after three injections. However, the frequency of injections needs further investigation with a greater number of patients.
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